Bio Protocol to Launch First BioAgent Sale Project Aubrai, with 20% of Total Supply Allocated for Sale
Foresight News reports that the decentralized science (DeSci) platform Bio Protocol will launch its first BioAgent sale project, Aubrai. Aubrai has a total supply of 2 million tokens, of which 20% will be allocated for sale, 6% for the liquidity pool, 15% for the treasury, 20.1% for initial backers, 10% for LEVF, 22% for VitaDAO, and 6.9% for Bio Protocol. The token TGE is scheduled for August 25.
Aubrai is a decentralized scientific agent jointly developed by VitaDAO and BIO, aimed at combating human aging.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
The US SEC releases its 2026 fiscal year review priorities document, removing the dedicated cryptocurrency section.
Two wallets related to the LIBRA scandal exchanged 60 million USDC for SOL after a period of inactivity
Mastercard selects Polygon to provide username verification for self-custody wallets
Trending news
MoreCrypto prices
More
